TY - JOUR T1 - Vaccination is Australia’s most important COVID-19 public health action, even though herd immunity is unlikely JF - medRxiv DO - 10.1101/2021.07.16.21260642 SP - 2021.07.16.21260642 AU - E.S. McBryde AU - M.T. Meehan AU - J.M. Caldwell AU - R. Ragonnet AU - P. Jayasundara AU - A. I. Adekunle AU - M. A. Kuddus AU - S. Ogunlade AU - J.M. Trauer AU - R.C. Cope Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/19/2021.07.16.21260642.abstract N2 - The Australian National Cabinet four-step plan to transition to post-pandemic re-opening begins with vaccination to achieve herd protection and protection of the health system against a surge in COVID-19 cases. Assuming a pre-vaccination reproduction number for the Delta variant of 5, we show that for the current Mixed program of vaccinating over 60s with AstraZeneca and 16-60s with Pfizer we would not achieve herd immunity. We would need to cover 85% of the population (including many 5-16 year-olds to achieve herd immunity).At lower reproduction number of 3 and our current Mixed strategy, we can achieve herd immunity without vaccinating 5-15 year olds. This will be achieved at a 60% coverage pursuing a strategy targetting high transmitters or 70% coverage using a strategy targetting the vulnerable first. A reproduction number of 7 precludes achieving herd immunity, however vaccination is able to prevent 75% of deaths compared with no vaccination.We also examine the impact of vaccination on death in the event that herd immunity is not achieved. Direct effects of vaccination on reducing death are very good for both Pfizer and AstraZeneca vaccines. However we estimate that the Mixed or Pfizer program performs better than the AstraZeneca program.Furthermore, vaccination levels below the herd immunity threshold can lead to substantial (albeit incomplete) indirect protection for both vaccinated and unvaccinated populations. Given the potential for not reaching herd immunity, we need to consider what level of severe disease and death is acceptable, balanced against the consequences of ongoing aggressive control strategies.The known: SARS CoV-2 variants are known to be more transmissible than the original Wuhan strain, making herd immunity challenging.The new: We find that vaccinating the older-vulnerable age groups first leads to fewer deaths and is the optimal strategy vaccine coverage is under 70%. Herd immunity achieved solely through vaccinating adults is unlikely, but can still be expected to prevent substantial numbers of deaths.The implications: Australia is unlikely to achieve herd immunity unless vaccination is combined with substantial public health measures. Even without herd immunity, vaccination remains a highly effective means to mitigate the impact of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementESM acknowledges Fellowshhip funding from NHMRC MM acknowledges Fellowship funding from ARC JT acknowledges Fellowshhip funding from NHMRC and project funding from MRFF PJ acknowledges salary support from MRFF these funding agencies have no role in or influence over the studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:not applicable as this is a mathematical modelling study using publically available data onlyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesno original data are used in this manuscript. Original code is in an open online repository, listed in the manuscript https://covid-19-aithm.shinyapps.io/vaccine_coverage_analysis/ https://github.com/michaeltmeehan/covid19/tree/main/immunization_australia ER -